SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness
Phase: PHASE2
Conditions: Mild Cognitive Impairment, Cognitive Impairment
Sponsor: Wake Forest University Health Sciences

Official Title:  SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness  
NCT04199767
IRB Approval Date:  10/02/2025
 

V2: 02-October-2025 
IND #: 119232 
Page 1 of 33 
SNIFF Multi-Device Study 2   
Study of Nasal Insulin to Fight Forgetfulness 
IND #: 119232 
PROJECT DIRECTOR / 
IND SPONSOR 
Suzanne Craft, Ph.D. 
Wake Forest University 
School of Medicine 
Medical Center Boulevard 
Winston-Salem, NC  27157-1207 
suzcraft@wakehealth.edu 
Tel: 336-713-8832 
PROTOCOL VERSION 
Protocol v2.0 
02-October-2025

V2: 02-October-2025 
IND #: 119232 
Page 2 of 33 
TABLE OF CONTENTS 
1.0 
INTRODUCTION ............................................................................................................... 8 
1.1 
Primary Aim ................................................................................................................ 8 
Secondary Aims .......................................................................................................... 8 
1.1.1 
Secondary Aim 1 ..................................................................................................... 8 
1.1.2 
Secondary Aim 2 ..................................................................................................... 8 
2.0 
BACKGROUND AND SIGNIFICANCE.............................................................................. 8 
2.1 
Rationale for Insulin..................................................................................................... 8 
2.2 
Insulin as a Therapeutic Agent .................................................................................... 9 
2.2.1 
Intranasal Pathways to the CNS .............................................................................. 9 
2.2.2 
Intranasal Delivery System Device ........................................................................ 10 
3.0 
PRELIMINARY STUDY ................................................................................................... 10 
3.1 
Participants ............................................................................................................... 11 
3.2 
Procedures ................................................................................................................ 12 
3.3 
Safety and Compliance ............................................................................................. 12 
3.4 
Statistical Analyses ................................................................................................... 12 
3.5 
Results: Cognitive and Functional Outcome Measures ............................................. 13 
3.6 
Results: AD Biomarkers ............................................................................................ 14 
3.7 
Results: FDG-PET CMRglc ....................................................................................... 14 
3.8 
Safety and Compliance ............................................................................................. 15 
3.9 
Implications ............................................................................................................... 15 
4.0 
PRELIMINARY STUDY 2 ................................................................................................ 15 
4.1 
Rationale for Dosage Selection ................................................................................. 17 
4.2 
Rationale for Primary and Secondary Outcome Measures ........................................ 17 
4.3 
Rationale for Design of Trial ...................................................................................... 17 
4.4 
Rationale for Biofluids  .............................................................................................. 17 
5.0 
STUDY OVERVIEW ........................................................................................................ 17 
5.1 
Study Population ....................................................................................................... 17 
5.2 
Diagnosis Criteria ...................................................................................................... 18 
5.3 
Inclusion Criteria ....................................................................................................... 18 
5.4 
Exclusion Criteria ...................................................................................................... 18 
5.5 
Recruitment and Retention Strategies ....................................................................... 18 
6.0 
STUDY TIMELINE ........................................................................................................... 19 
7.0 
DESCRIPTION OF STUDY VISITS ................................................................................. 19 
7.1 
Screening (Visit 1) ..................................................................................................... 19 
7.2 
Baseline (Visit 2) ....................................................................................................... 20 
7.3 
Visit 3 ........................................................................................................................ 19 
8.0 
STUDY SPECIFIC PROCEDURES…………………………………………………………….20 
8.1 
Memory Evaluation - AVLT…………………………………………………………………20 
    8.2 
  Clinical and Functional Evaluations………………………………………………………..20 
8.2.1 
Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) ................................... 20 
9.0 
STUDY METHODS .......................................................................................................... 20 
9.1 
Safety Assessments .................................................................................................. 20 
9.2 
Physical and Neurological Examination ................................................................... 201 
9.3 
Electrocardiogram (ECG) .......................................................................................... 20 
9.4 
Clinical Laboratory Evaluations ................................................................................. 20 

V2: 02-October-2025 
IND #: 119232 
Page 3 of 33 
10.0 BIOMARKER STUDIES .................................................................................................. 21 
10.1 
CSF ........................................................................................................................... 21 
10.2 
Blood Collection at Lumbar Puncture Visits ............................................................... 21 
10.3 
Genetic Samples, Storage and Future Use ............................................................... 22 
11.0 STATISTICAL PLAN ....................................................................................................... 22 
11.1 
Power Analyses ........................................................................................................ 21 
12.0 POTENTIAL RISKS ........................................................................................................ 21 
12.1 
Safety of Intranasal Insulin ........................................................................................ 22 
12.2 
Risks associated with use of the ViaNase® device .................................................... 23 
12.3 
Lumbar Puncture ....................................................................................................... 22 
12.4 
Blood Draw ............................................................................................................... 23 
13.0 PERSONNEL REQUIREMENTS ..................................................................................... 23 
14.0 STUDY DRUG ............................................................................................................... 234 
14.1 
Humulin® R U-100 Insulin ........................................................................................ 234 
14.2 
Randomization .......................................................................................................... 24 
14.3 
Blinding ..................................................................................................................... 24 
14.4 
Study Drug Dispensing .............................................................................................. 24 
14.5 
Intranasal Administration ........................................................................................... 24 
14.6 
Storage ..................................................................................................................... 24 
14.7 
Drug Accountability ................................................................................................... 24 
15.0 ADVERSE EVENTS ...................................................................................................... 245 
15.1 
Definition ................................................................................................................. 245 
15.2 
Following Up on AEs ................................................................................................. 25 
16.0 SERIOUS ADVERSE EVENTS (SAE) ............................................................................. 25 
16.1 
Definition ................................................................................................................... 25 
16.2 
Reporting SAEs ......................................................................................................... 25 
17.0 ETHICS & REGULATORY CONSIDERATIONS ........................................................... 256 
17.1 
Ethical Standard ...................................................................................................... 256 
17.2 
Institutional Review Board (IRB) .............................................................................. 256 
17.3 
Informed Consent & HIPAA Authorization ................................................................. 27 
17.4 
Participant Confidentiality | HIPAA ............................................................................ 27 
18.0 GENETIC RESEARCH & STORAGE OF GENETIC MATERIAL .................................. 267 
18.1 
Storage of Biospecimen Samples.............................................................................. 27 
19.0 RISKS AND BENEFITS ASSOCIATED WITH THIS STUDY .......................................... 27 
19.1 
Potential Benefits of the Proposed Research to Human Subjects.............................. 27 
19.2 
Inclusion of Women and Minorities ............................................................................ 27 
19.3 
Inclusion of Children as Participants in Research Involving Human Subjects ............ 27 
    19.4   Data and Safety Monitoring Plan and Board……………………………………………..28  
20.0 PUBLICATION POLICY .................................................................................................. 28 
21.0 SHARING OF FINAL RESEARCH DATA ....................................................................... 28 
22.0 TABLE 4: SCHEDULE OF PROCEDURES AND ASSESSMENTS ................................ 29 
23.0 LITERATURE CITED ...................................................................................................... 30 

V2: 02-October-2025 
IND #: 119232 
Page 4 of 33 
STUDY GLOSSARY 
 
3MSE 
MODIFIED MINI-MENTAL STATUS EXAM 
AΒ 
BETA AMYLOID 
AD 
ALZHEIMER’S DISEASE 
ADAS-COG 
ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE 
SUBSCALE 
ADCS 
ALZHEIMER’S DISEASE COOPERATIVE STUDY 
ADCS-ADL 
ALZHEIMER’S DISEASE COOPERATIVE STUDY - ACTIVITIES OF 
DAILY LIVING 
ADEAR 
ALZHEIMER’S DISEASE EDUCATION AND REFERRAL CENTER 
ADNI 
ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 
AE 
ADVERSE EVENT 
AMCI 
AMNESTIC MILD COGNITIVE IMPAIRMENT 
ANCOVA 
ANALYSIS OF COVARIANCE 
APOE/APOE4 
APOLIPOPROTEIN (APOE) EPSILON 4 (APOE4) 
BDNF 
BRAIN-DERIVED NEUROTROPHIC FACTOR 
BID | BID 
BIS IN DIE (TWICE A DAY) 
BUN 
BLOOD UREA NITROGEN 
CDR-SB 
CLINICAL DEMENTIA RATING – SUM OF BOXES 
CFR 
CODE OF FEDERAL REGULATIONS 
CMRGLC 
CEREBRAL METABOLIC RATE OF GLUCOSE UTILIZATION 
CNS 
CENTRAL NERVOUS SYSTEM 
CPD 
CONTROLLED PARTICLE DISPERSION 
CPK 
CREATINE PHOSPHOKINASE 
CREB 
CAMP RESPONSE ELEMENT-BINDING PROTEIN 
CRF/E-CRF 
CASE REPORT FORM/ELECTRONIC CASE REPORT FORM  
CSF 
CEREBRAL SPINAL FLUID 
DNA 
DEOXYRIBONUCLEIC ACID 
DSMB 
DATA & SAFETY MONITORING BOARD 
DSM-IV 
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS, FOURTH EDITION 
DSRS 
DEMENTIA SEVERITY RATING SCALE 
EAG 
ESTIMATED AVERAGE GLUCOSE 
ECG 
ELECTROCARDIOGRAM 
EDC 
ELECTRONIC DATA CAPTURE 

V2: 02-October-2025 
IND #: 119232 
Page 5 of 33 
EDTA 
ETHYLENE DIAMINE TETRA ACETIC ACID 
ELISA 
ENZYME-LINKED IMMUNOSORBENT ASSAY 
FCSRT 
FREE AND CUED SELECTIVE REMINDING TEST  
FDA 
FOOD AND DRUG ADMINISTRATION 
FDG PET 
FLUORO DEOXY GLUCOSE POSITRON EMISSION TOMOGRAPHY 
GCP 
GOOD CLINICAL PRACTICE 
GEE 
GENERALIZED ESTIMATING EQUATION 
GGT 
GAMMA GLUTAMYL TRANSPEPTIDASE 
GSK3Β 
GLYCOGEN SYNTHASE KINASE 3 BETA 
HGA1C 
HEMOGLOBIN A1C 
HC 
HOMOCYSTEINE 
HCT 
HEMATOCRIT 
HCY 
HOMOCYSTEINE 
HEENT 
HEAD | EARS | EYES | NOSE | THROAT 
HGB 
HEMOGLOBIN 
HIPAA 
HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT 
HOMA-IR 
HOMEOSTATIS MODEL ASSESSMENT OF INSULIN RESISTANCE 
ICF 
INFORMED CONSENT FORM 
ICH 
INTERNATIONAL CONFERENCE ON HARMONISATION 
IDE 
INSULIN DEGRADING ENZYME 
IGF-1 
INSULIN-LIKE GROWTH FACTOR-1 
INI 
INTRANASAL INSULIN  
IRB 
INSTITUTIONAL REVIEW BOARD 
ITT 
INTENT-TO-TREAT 
LDH 
LACTATE DEHYDROGENASE 
LP 
LUMBAR PUNCTURE 
LTP 
LONG TERM POTENTIATION 
MCV 
MEAN CORPUSCULAR VOLUME 
ML 
MILLILITER 
MMA 
METHYLMALONIC ACID 
MMSE 
MINI MENTAL STATE EXAMINATION 
MPRAGE 
MAGNETIZATION PREPARED RAPID GRADIENT ECHO 
MR/MRI 
MAGNETIC RESONANCE / MAGNETIC RESONANCE IMAGING 
NBAC 
NATIONAL BIOETHICS ADVISORY COMMISSION 

V2: 02-October-2025 
IND #: 119232 
Page 6 of 33 
NIA 
NATIONAL INSTITUTE ON AGING 
NIH 
NATIONAL INSTITUTES OF HEALTH 
NINCDS/ADRDA 
NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE 
DISEASES AND STROKE / ALZHEIMER'S DISEASE AND RELATED 
DISORDERS ASSOCIATION 
NBDA 
N-METHYL – D-ASPARTATE 
NSAID 
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
OHRP 
OFFICE FOR HUMAN RESEARCH PROTECTIONS 
PBMC 
PERIPHERAL BLOOD MONONUCLEAR CELL 
PD 
PROJECT DIRECTOR  
PCP 
PRIMARY CARE PHYSICIAN 
PET 
POSITRON EMISSION TOMOGRAPHY 
PHI 
PROTECTED HEALTH INFORMATION 
PI 
PRINCIPAL INVESTIGATOR 
PID 
PARTICIPANT ID  
RBC 
RED BLOOD CELL 
RE 
RANDOM EFFECTS 
ROI 
REGIONS OF INTEREST 
SAE 
SEVERE ADVERSE EVENT 
SD 
STANDARD DEVIATION 
SGOT 
SERUM GLUTAMIC OXALOACETIC TRANSAMINASE 
SGPT 
SERUM GLUTAMIC PYRUVIC TRANSAMINASE 
T 
TESLA 
TSH 
THYROID STIMULATING HORMONE 
U/A 
URINALYSIS 
WBC 
WHITE BLOOD COUNT 
 
 
 

V2: 02-October-2025 
IND #: 119232 
Page 7 of 33 
 
 
 
 
 
 
TITLE 
 
 
 
Device Study for Intranasal Delivery of Insulin 
PROJECT DIRECTOR 
Suzanne Craft, Ph.D. 
STUDY SPONSOR 
 
STUDY PHASE 
 
 
 
Phase II 
INDICATION 
 
 
 
Preclinical AD, Amnestic mild cognitive impairment (aMCI) or mild 
Alzheimer’s disease (AD) 
AIM OF STUDY 
To determine the ability of three intranasal delivery devices to increase 
levels of insulin in cerebrospinal fluid (CSF) 
PRIMARY OBJECTIVE 
To compare changes in CSF insulin levels after receiving a 20 or 40 
International Unit dose of insulin delivered with one of three devices, 
compared to baseline levels.  
SECONDARY OBJECTIVES 
1. To test the hypothesis that memory performance measured 
with a list learning test (Auditory Verbal Learning Test) will be 
enhanced after insulin administration  
2. To test the hypothesis that CSF Aβ42 will increase after insulin 
administration 
PRIMARY OUTCOME MEASURE 
CSF insulin 
SECONDARY OUTCOME MEASURES  
Memory test, CSF Aβ42  
EXPLORATORY MEASURES 
CSF Aβ40, total tau, and phospho-tau 181 
STUDY DESIGN 
 
Single-site, double-blind study  
SAMPLE SIZE 
 
• 
n=30 
SUMMARY OF KEY ELIGIBILITY 
CRITERIA  
 
• 
Cognitively normal or 
• 
 Diagnosis of aMCI (Petersen criteria)  
• 
Age: 45 to 85 yrs (inclusive) 
DRUG DOSAGE & FORMULATION 
20  or 40 International Units Humulin® R U-100 
DURATION OF PARTICIPATION 
Participants will complete three study visits over approximately two 
months.  The study visits will include one 2-hour screening visit and two 
4-hour IP administration visits, conducted approximately 30-days apart. 
PLACEBO 
No placebo will be used, CSF insulin levels after insulin administration 
will be compared to baseline levels prior to administration 
ROUTE OF ADMINISTRATION 
 
Intranasal 
PROCEDURES 
 
Physical and neurological exam, nasal examination, lumbar puncture, 
Vitals, Clinical Labs, CSF and blood analysis & banking and 
genotyping. 

V2: 02-October-2025 
IND #: 119232 
Page 8 of 33 
 
1.0       INTRODUCTION  
An urgent need exists to find effective treatments for AD that can arrest or reverse the disease at its 
earliest stages. The emotional and financial burden of AD to patients, family members, and society is 
enormous, and is predicted to grow exponentially as the median population age increases. Current 
FDA-approved therapies are modestly effective at best. This study will provide information to assist in 
examining a novel therapeutic approach using intranasally administered insulin (INI) that has shown 
promise in short-term clinical trials. In a recent longer term trial in which INI was delivered with two 
devices (Kurve ViaNase device and Impel Precision Olfactory Delivery (POD) device, a different pattern 
of results was observed between the two devices, suggesting that differences in delivery systems can 
impact the therapeutic effects of insulin. In the time since this study new devices have been developed 
that may more effectively deliver insulin to the CNS. The proposed proof of concept study will examine 
whether three devices developed by Aptar Pharmaceuticals are able to effectively increase CSF insulin 
levels over a 30 minute timeframe after administration, a timeframe which has been show to represent 
the greatest increase in CSF insulin in a previous study (Born et al. Nature Neuroscience, 2002 
Jun;5(6):514-6). It is also possible that the efficacy of new devices may differ according to dose of 
insulin. Thus we will examine effects for two different doses of insulin (20 and 40 IU).  If successful, 
information gained from the study will inform the design of future Phase III trials of intranasal insulin.  
 
1.1 
Primary Aim 
To test the hypothesis that CSF insulin levels will increase after receiving a 20 or 40 International Units 
dose of insulin delivered with one of 3 intranasal delivery devices developed by Aptar Pharmaceutical, 
compared to baseline levels. 
 
1.1.1 Secondary Aim 1 
1. To examine differences in memory performance measured with a list learning test (Auditory 
Verbal Learning Test) after administration of 20 or 40 IU insulin.  
 
1.1.2 Secondary Aim 2 
 
1. To test the hypothesis that CSF Aβ42 will increase after insulin administration relative to 
baseline. 
 
2.0 
BACKGROUND AND SIGNIFICANCE 
 
2.1 
Rationale for Insulin 
The rationale for the study is derived from growing evidence that insulin carries out multiple functions 
in the brain, and that insulin dysregulation may contribute to AD pathogenesis (Craft and Watson 2004). 
Insulin receptors are densely localized in the hippocampus and in entorhinal, frontal, and other cortical 
areas; they are found primarily in synapses, where insulin signaling modulates synaptogenesis and 
synaptic remodeling (Chiu, Chen et al. 2008, Zhao and Townsend 2009). Insulin facilitates memory at 
optimal levels, possibly through synaptic effects and enhanced hippocampal glucose utilization (Grillo, 
Piroli et al. 2009).  
 
The importance of insulin in normal brain function is underscored by evidence that insulin dysregulation 
contributes to the pathophysiology of AD, a disorder characterized in its earliest stages by synaptic loss 
and memory impairment. Hoyer and colleagues first identified a reduction in insulin receptors and 
signaling markers in the AD brain (Frolich, Blum-Degen et al. 1998). This initial finding has been 
confirmed and extended by other investigators, who have demonstrated reduced CSF insulin in patients 
with AD and MCI (Craft, Peskind et al. 1998, Gil-Bea, Solas et al. 2010), and reduced insulin and IGF-
I messaging with increasing AD pathology and cholinergic deficit (Rivera, Goldin et al. 2005). Insulin 
has a close relationship with β-amyloid, the toxic peptide produced by cleavage of the amyloid precursor 

V2: 02-October-2025 
IND #: 119232 
Page 9 of 33 
protein (Zhao and Townsend 2009). In AD, insoluble Aβ peptides deposit in brain parenchyma and 
vasculature. Soluble Aβ species, particularly oligomers of the 42 amino acid specie (Aβ42), have 
synaptotoxic effects, possibly resulting in synapse loss, which is the earliest structural defect observed 
in AD (Selkoe 2008). Insulin reduces oligomer formation and protects against Aβ-induced 
synaptotoxicty and LTP disruption (Gasparini, Gouras et al. 2001, De Felice, Vieira et al. 2009, Lee, 
Kuo et al. 2009). Interestingly, Aβ also regulates brain insulin signaling. Soluble Aβ binds to the insulin 
receptor and disrupts insulin signaling and LTP induction in mouse hippocampal slice preparations 
(Townsend, Mehta et al. 2007). These effects could be prevented by exposing tissue to insulin prior to 
Aβ exposure. Insulin pre-treatment also prevented synthetic soluble Aβ oligomers from downregulating 
plasma membrane insulin receptors and reducing dendritic spines in primary hippocampal neurons (De 
Felice, Vieira et al. 2009). Insulin may also modulate Aβ degradation by regulating expression of insulin 
degrading enzyme (IDE), a metalloprotease that catabolizes insulin (Zhao, Teter et al. 2004). 
Collectively, these findings suggest that soluble Aβ may induce central nervous system (CNS) insulin 
resistance and synapse loss, and that treatment with insulin may prevent these pathological processes. 
 
A role for insulin has also been suggested for other AD-related mechanisms. Insulin inhibits 
phosphorylation of tau, through its regulation of glycogen synthase kinase 3β, a downstream target in 
the insulin signaling pathway (Hong and Lee 1997). Insulin dysregulation is also associated with 
oxidative stress, inflammation, and impaired neurogenesis (Craft and Watson 2004). Thus, insulin has 
been implicated in numerous processes related to AD pathophysiology, suggesting that correction of 
insulin dysregulation may be a therapeutic strategy with considerable clinical and scientific significance. 
 
2.2 
Insulin as a Therapeutic Agent 
The study uses insulin as a therapeutic agent and intranasal administration focusing on nose to brain 
transport as a mode of delivery. As reviewed above, insulin has pleiotropic effects on pathways 
implicated in AD pathogenesis. As such, augmenting CNS insulin is an alternative approach to AD 
therapy, in contrast to the majority of therapeutic approaches that focus on narrowly defined 
mechanisms such as acetylcholine modulation or amyloid accumulation. Restoring normal brain insulin 
levels in persons with AD may improve cognition and AD pathologic processes. Such an approach is 
possible with an intranasal administration technique. 
 
2.2.1 Intranasal Pathways to the CNS  
Olfactory sensory neurons are directly exposed to the external environment in the upper nasal cavity 
while their axons extend through the cribriform plate to the olfactory bulb. Following intranasal 
administration, drugs can be directly transported to the CNS, bypassing the periphery. Several 
extraneuronal and intraneuronal pathways from the nasal cavity to the CNS are possible. The 
extraneuronal pathways appear to rely on bulk flow transport through perineural channels to the brain 
or CSF. In recent studies, labeled INI or a closely related peptide, insulin-like growth factor-I (IGF-I), 
were administered to rodents (Thorne, Pronk et al. 2004, Francis, Martinez et al. 2008). Within 30 
minutes, signal was detected along olfactory and trigeminal channels, as well as in the hippocampus, 
amygdala and rostral and caudal cortex. An additional extracellular pathway was identified with quick 
access to the CSF after absorption into the submucosa along the olfactory nerve and cribriform plate 
(Born, Lange et al. 2002, Frey 2002, Thorne, Pronk et al. 2004). These extracellular pathways provide 
direct access to the CNS within minutes of intranasal administration. Additionally, an intraneuronal 
pathway delivers drugs to the CNS hours or days later (Broadwell and Balin 1985, Shipley 1985, Baker 
and Spencer 1986, Balin, Broadwell et al. 1986). Viruses and microorganisms (Fairbrother and Hurst 
1930, Faber 1938, Bodian and Howe 1941), amino acids (Weiss and Holland 1967), and proteins 
(Kristensson and Olsson 1971, Shipley 1985, Thorne, Emory et al. 1995) can also enter the CNS via 
nasal routes. In particular, substances with lower molecular weights are more likely to be transported 
to the CNS along intranasal pathways (Sakane, Akizuki et al. 1995). Insulin’s molecular weight of about 
5800 g/mol makes it a good candidate for intranasal delivery. Animal studies show labeled uptake to 
hippocampus and rostral and caudal cortex following INI administration (Francis, Martinez et al. 2008). 
In a murine diabetes model, INI reduced brain atrophy, while increasing synaptic markers and activation 

V2: 02-October-2025 
IND #: 119232 
Page 10 of 33 
of Akt, CREB, and GSK3β. Memory enhancement was also observed on Water Maze and radial arm 
tasks (Francis, Martinez et al. 2008). Human functional and cognitive studies of INI also support insulin’s 
transport to the CNS. INI treatment increases CSF insulin levels and induces changes in auditory-
evoked brain potentials compared to placebo (Kern, Born et al. 1999). INI improves verbal memory 
acutely in persons with AD and aMCI without affecting plasma insulin or glucose levels at the dose 
included in the study (Reger, Watson et al. 2006). Regarding chronic effects, several studies reported 
that 2 months of daily insulin administration (160 International Units/day) significantly improves verbal 
memory in young healthy adults (Benedict, Hallschmid et al. 2004, Stockhorst, de Fries et al. 2004, 
Benedict, Kern et al. 2008, Hallschmid, Benedict et al. 2008, Stockhorst, de Fries et al. Submitted for 
publication). Finally, Section 3.0 presents results in a preliminary study in which insulin was 
administered to adults with AD or aMCI for 4 months. 
 
2.2.2 Intranasal Delivery System Devices 
The three intranasal delivery devices to be investigated in this study have been developed and 
extensively tested by Aptar Pharmaceuticals, a company specializing in drug delivery. Specifications 
and instructions for all three devices are provided in attached materials:  
 
1) The CPS pump is a multidose device utilizing an air-filtered preservative free system, in which 
a .2 micrometer filter membrane filters the airflow and insulin will be delivered through a spring 
loaded tip. This device is currently used in the delivery of Esketamine, a Janssen product 
approved by the FDA for the treatment of refractory depression. 
2) The VP7 pump is a multidose device that uses a precompressed system assembled with a 
specific long tipped actuator for nose to brain configuration, 
3) The UDS pump is a single dose device that combines a container holder subunit and an actuator 
subunit. 
 
3.0 
PRELIMINARY STUDIES 
A preliminary study examined the impact of 4-month INI administration using the ViaNase device (10 
or 20 International Units bid vs. placebo) on the primary outcome measures of delayed story recall and 
the Dementia Severity Rating Scale (DSRS) as well as on measures of global cognition and function 
used in traditional AD clinical trials. In a subset of participants, effects on CSF AD biomarkers (Aβ42 
and tau/Aβ42 ratio), and on cerebral metabolic rate of glucose utilization (CMRglc) assessed by 
F18FDG PET were also examined (Craft, Baker et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

V2: 02-October-2025 
IND #: 119232 
Page 11 of 33 
 
3.1 
Participants 
A total of 111 older adults were 
randomized in the study (Fig. 1). 
Data from 104 participants were 
analyzed. 
 
Sample composition (aMCI, n=64; AD 
with 
MMSE 
>15, 
n=40), 
size, 
and 
diagnostic criteria were based on a 
previous study (Reger, Watson et al. 
2008). Forty participants (15 placebo, 
13 
low dose insulin and 12 high dose 
insulin) completed the PET sub-study, 
and 
23 participants (n=8 placebo and 15 
insulin) completed the LP sub-study. 
Diagnoses were determined by expert 
physician 
and 
neuropsychologist 
consensus. Participants, caregivers, 
and 
all 
personnel 
involved 
in 
data 
collection were blinded to treatment assignment. Groups did not differ in education, body mass index, 
MMSE, gender, diagnosis, cholinesterase inhibitor treatment, or apolipoprotein E (APOE) ε4 allele 
carriage (Table 1).  
 
Table 1 | Participant Characteristics 
 
 
Participants in the high dose insulin group were younger than placebo-assigned participants (p=0.02), 
whereas no differences were observed between placebo and low dose insulin groups. Age was included 
as a covariate in all analyses. 
Figure 1 | Trial Enrollment Flow 

V2: 02-October-2025 
IND #: 119232 
Page 12 of 33 
3.2 
Procedures 
Participants were randomized to receive 10 International Units INI bid for a total daily dose of 20 
International Units INI (n=36), 20 International Units INI bid for a total dose of 40 International Units 
(n=38) or placebo (saline bid, n=30) for 4 months. Participants were stratified by APOE-ε4 carriage. 
Saline or insulin (Novolin R, Novo) was administered after breakfast and dinner with ViaNase™, an 
intranasal delivery system (Craft, Baker et al. 2012). Parallel versions of the cognitive protocol were 
administered at baseline, and months 2 and 4 of treatment. Co-primary outcome measures were 
delayed story recall and the DSRS which had previously demonstrated beneficial effects of insulin 
(Reger, Watson et al. 2008). Secondary measures included the AD Assessment Scale for Cognition 
(ADAS-Cog) (Reger, Watson et al. 2008), a test comprised of measures of memory, orientation, and 
language, with higher scores reflecting impairment ranging from 0 (best) to 70 (worst), and the ADCS-
Activities of Daily Living scale (ADCS-ADL) (Galasko, Bennett et al. 1997). Baseline and post-treatment 
fasting CSF was analyzed for Aβ42 and tau with multi-parameter bead-based immunoassay INNO-BIA 
AlzBio3 (Innogenetics NV). Resting PET images were obtained using a GE Advance PET scanner (GE 
Medical Systems, Milwaukee, WI) using a previously described protocol (Baker, Cross et al. 2011). 
 
3.3 
Safety and Compliance 
Support persons supervised participants’ intranasal administration. Blood glucose was measured daily 
for the first week and then weekly; no group changes were observed over the course of the study (Craft, 
Baker et al. 2012). Compliance was monitored by quantifying unused drug. Safety data were reviewed 
semi-annually by a Data and Safety Monitoring Board. Adverse event reporting followed standard 
guidelines. 
 
3.4 
Statistical Analyses 
For the intent-to-treat (ITT) sample, co-primary (delayed story recall and DSRS) and secondary (ADAS-
Cog and ADAS-ADL) scores were log transformed. Scores were first subjected to mixed model repeated 
ANCOVA including all treatment groups (placebo, low dose insulin or high dose insulin) as the between 
subjects factor, and time (baseline, month 2, month 4) as the repeated factor using the SAS v9.2 
General Linear Models procedure. After a significant (p<0.05) time by treatment group interaction 
reflecting a different pattern of change, each of the two insulin groups was compared separately with 
the placebo group using repeated measures ANCOVAs. Effect sizes (Cohen’s f2) were calculated for 
all significant effects. Age was included as a covariate in all analyses. Diagnosis (aMCI or AD), gender, 
APOE-ε4 carriage status (yes or no), baseline 3MSE score, and years of education were also included 
as covariates. Non-significant covariates were dropped from the model. Significant relationships with 
covariates were explored with Pearson correlation (continuous variables) or follow-up ANOVAs (class 
variables). Missing values were treated with multiple imputation (Rubin 1987). For exploratory CSF 
biomarker analyses, because only a subset of participants elected to undergo LP and no differences 
were observed between the two insulin dose arms, the groups were combined into a single insulin-
treated group to maximize power. Biomarkers were analyzed with the repeated ANCOVA strategy 
described above and, due to the small sample size, exploratory Spearman correlations were conducted 
to examine relationships among changes in biomarkers and outcome measures. Only study completers 
underwent post-treatment FDG-PET. Pre and post treatment scans were co-registered within subject 
and anatomically standardized to Talairach and Tournoux stereotactic coordinates (Talairach and 
Tournoux 1988, Minoshima, Koeppe et al. 1994). Pixel intensity was normalized to pontine values 
(Minoshima, Frey et al. 1995). Interval regional CMRglc changes within groups were assessed using 
voxel-wise one-sample t statistics (pre-/post-treatment pair) and probability integral conversion to z 
scores (Worsley, Evans et al. 1992). Interval changes in regional CMRglc were then compared between 
1) low insulin vs. placebo groups, and 2) high insulin vs. placebo groups. Based on the number of voxels 
and smoothness of the statistical map, a Type I error rate was controlled at 0.05 to account for multiple 
comparisons (Worsley, Evans et al. 1992). The resulting statistical maps were visualized in three-
dimensional stereotactic surface projections. 
 
 

V2: 02-October-2025 
IND #: 119232 
Page 13 of 33 
3.5 
Results: Cognitive and Functional Outcome Measures 
The three groups did not differ at baseline on any outcome measure; change from baseline is 
represented in figures for ease of interpretation. A significant overall treatment group by time interaction 
was observed for primary outcome delayed story recall (p=0.005). Compared to placebo, the low dose 
group had improved delayed recall (Fig. 2A; treatment by time p=0.02, 
Cohen’s f2=0.36), whereas no effect was observed for the high dose group. Exploratory post-hoc 
analyses were then conducted to more closely examine the relationship of insulin dose to story recall, 
as this was a primary goal of this pilot clinical trial. Given findings that delayed recall may not be a 
sensitive measure for AD subjects due to increased variability and floor effects (Sano, Raman et al. 
2011) we constructed a total story recall score (immediate and delayed), which showed improvement 
for the high-dose group (time by treatment interaction p<0.05, mean log total story recall change score 
with SEM = -.15(.1) for placebo vs.12 (.09) for the high dose group). A significant overall treatment by 
time interaction was observed for the other primary outcome measure, the DSRS (p=0.008). Compared 
with placebo, DSRS scores were preserved for both low and high dose groups (Fig.2B; treatment by 
time ps=0.01 and 0.01, Cohen’s f2=0.38 and 0.41). For secondary measures, significant effects were 
observed for the ADAS-Cog (overall treatment by time interaction p=0.004). Both low and high insulin 
groups had less decline in cognition compared with placebo (Fig. 2C; treatment by time ps=0.04 and 
p=0.002, Cohen’s f2=0.27 and .40). Treatment effects on the ADAS-Cog interacted with age; for the 
high dose insulin group, greater improvement (lowered score) tended to be associated with younger 
age (r=.31, p=0.06). For the ADCS-ADL, no overall effects of treatment on daily function were observed. 
However, a significant interaction with diagnosis was observed for this measure (overall treatment by 
time by diagnosis interaction p=0.02). Participants with AD receiving either dose of insulin had 
preserved function compared with placebo-assigned participants with AD who showed slight decline, 
whereas participants with aMCI showed no change regardless of treatment assignment (interactions 
for the participants with AD in low and high dose groups compared with placebo, ps=0.01 and 0.02, 
Cohen’s f=0.45 and 0.43; Fig. 2D). Adjustment for APOE-ε4 status, baseline MMSE score, 
cholinesterase inhibitor treatment, gender, and education did not affect the pattern of any result. 
Figure 2 | Change (Month 4-baseline) in log scores for (A) delayed story recall, (B) DSRS, (C) ADAS-Cog 
and (D) ADCS-ADL. 
 
 
 
 
 
 

V2: 02-October-2025 
IND #: 119232 
Page 14 of 33 
3.6 
Results: AD Biomarkers  
CSF Aβ42, Aβ40 and tau did not change for the placebo or insulin-treated groups as a whole. In 
exploratory analyses, however, for insulin-treated participants, increased CSF Aβ42 concentrations 
were associated with improved delayed story recall and ADCS-ADL scores, whereas decreased Aβ42 
was associated with worse performance (Spearman rhos=.59, p=0.02 and .60, p=0.02). Similarly, 
decreased tau/Aβ42 ratios over the 4-month study period correlated with improved delayed story recall 
and better daily function on both ADAS-ADL and DSRS for insulin-treated participants (Spearman 
rhos=-.52, p=0.05, -.50, p=0.07, and .53, p=0.05). No significant correlations were observed for the 
placebo group. 
 
3.7 
Results: FDG-PET CMRglc 
Compared with placebo-assigned participants, the lower dose insulin group showed reduced 
progression of hypometabolism in bilateral frontal, right temporal, bilateral occipital, and right precuneus 
and cuneus regions over the 4-month treatment period (Fig. 3 and Table 2). The higher dose insulin 
group showed even greater treatment effects (higher Z scores) indicating less hypometabolism 
progression in most regions and in left parietal cortex. 
 
Figure 3 | Areas of hypometabolism at baseline (scan 1) and month 4 (scan 2), along with changes in 
hypometabolism (time 2-time 1) within each group and differences in change between placebo and low or 
high insulin groups (nasal insulin-placebo).  Hotter floors indicate areas of greater hypometabolism from 
time 1 to time 2, and from placebo to insulin groups. 
 
 
Table 2 | Z scores and stereotactic coordinates for areas of reduced progression for low and high does 
insulin groups compared to placebo 
 
 
 

V2: 02-October-2025 
IND #: 119232 
Page 15 of 33 
3.8 
Safety and Compliance 
No treatment-related serious adverse events (SAEs) occurred during the study; most adverse events 
(AEs) were minor, such as mild rhinitis. AEs with an occurrence of >5% in any group are listed in Table 
3. The total AE mean was higher for the low dose group compared with placebo (low dose mean total 
AEs with standard error=1.44±0.20, placebo =0.80±.22, p=0.04), with a similar trend for the high dose 
and placebo group comparison (high dose mean total AEs =1.21±0.16, placebo =0.80±.22, p=0.10). 
Mean compliance (number of completed doses) ranged from 95-97% and did not differ across groups. 
Table 3 | Total number of adverse events and percent of sample for all events occurring for at least 5% of 
the participants in any treatment group. 
 
 
3.9 
 Implications 
These results suggest that adults with aMCI or AD may benefit from INI treatment. Compared with 
placebo, the lower dose of insulin improved delayed memory, and both insulin doses preserved 
caregiver-rated ability to carry out daily functions. General cognition as assessed with the ADAS-Cog, 
the primary outcome measure for the current trial, was also preserved by both doses of INI. In 
exploratory analyses, changes in CSF Aβ42 and tau/Aβ42 ratios were associated with cognitive and 
functional changes for insulin-treated participants. Placebo-assigned participants showed decreased 
CMRglc values in frontal, temporal, and parietal cortices as well as precuneus and cuneus over the 4-
month period, whereas insulin-treated participants showed no decline. The longstanding FDG PET 
finding of posterior cingulate, precuneus and cuneus hypometabolism in AD has been hypothesized to 
be due to functional disconnection of the hippocampal formation, so enhanced metabolism and memory 
with INI may reflect enhanced hippocampal input to this region. Similarly there are strong connections 
between the posterior cingulate, precuneus, cuneus and prefrontal and superior temporal cortex 
(Cavanna and Trimble 2006), which may also be affected by INI. Finally, no treatment-related SAEs 
occurred.  
 
4.0 
PRELIMINARY STUDY 2 
A follow-up study has recently concluded and preliminary results have been analyzed. 
 
Objectives: This study tested the effects of 40 International Units of intranasal insulin administered 
daily for 12 months, compared with placebo, on cognition, daily function and safety in adults with MCI 
or mild AD. Longer-term effects were examined in a six-month open-label extension offered to all 
participants. Safety and feasibility issues relating to the use of intranasal delivery devices were also 
evaluated. The trial is nearing completion; all participants have concluded the blinded phase. 
 
 
 
 
 
Methods: Twenty-six sites enrolled 289 participants with MCI or mild AD in this randomized, double-
blind, Phase II/III trial (NCT01767909). Adults 45 to 85 years of age with diagnoses of amnestic MCI 

V2: 02-October-2025 
IND #: 119232 
Page 16 of 33 
or AD (National Institute on Aging-Alzheimer’s Association criteria) with Mini-Mental State Exam 
(MMSE) scores >19, Clinical Dementia Ratings (CDR) of 0.5 or 1, and delayed Logical Memory 
scores within a specified education-adjusted range were eligible. Participants with diabetes requiring 
medication were excluded, as were participants who had used insulin within one year of the screening 
visit. Participants were randomized on a 1:1 basis using a covariate-adaptive algorithm that weighted 
MMSE, apolipoprotein E-ε4 (APOE-ε4) allele carriage, study site, sex, and age based on previous 
work indicating these factors may impact treatment response. Participants received 40 International 
Units of insulin or insulin diluent placebo (Humulin R U-100 or insulin diluent, Eli Lilly, Indianapolis, 
USA) daily for 12 months. At the end of the 12-month blinded phase, all participants were offered 
open-label insulin treatment for 6 months.  The primary outcome (Alzheimer’s Disease Assessment 
Scale for Cognition-12/ADAS-Cog12) was administered at baseline and then at 3 month intervals. 
Secondary functional outcomes (Alzheimer’s Disease Cooperative Study-Activities of Daily Living 
Scale for MCI; CDR Sum of Boxes) were assessed at 6 month intervals, as was a memory composite 
(Free and Cued Selective Reminding Test and Story Recall). Cerebrospinal fluid biomarkers (Aβ42 
and Aβ42/tau ratio) and magnetic resonance imaging hippocampal and entorhinal cortex volumes 
were measured at baseline and after 12 months.  
 
Device issues. Intranasal delivery device monitoring revealed no safety issues. However, for the first 
49 participants, the delivery device had frequent malfunctions (i.e. failure to turn on) that impacted 
dosing reliability. At that time, a newly available device was introduced (Precision Olfactory 
Device/POD, Impel NeuroPharma, Seattle, USA) which was used by the remaining 240 participants 
with good reliability.  
 
Results: Demographic characteristics of enrolled participants are 
presented in Table 1. Retention was excellent, with only 25 
participants discontinuing treatment during the blinded phase, 
and 15 also discontinuing study visits during the blinded phase. 
Quarterly DSMB reviews did not detect any safety issues and 
approved unmodified continuation of the trial.  
 
Data from the subgroup of participants who used the POD were 
analyzed separately from the ViaNase group. The primary 
analysis of the POD group showed was negative; no difference in ADAS-Cog12 scores were 
observed after 12 months of INI treatment compared with placebo (Fig.1). In contrast, analysis of the 
ViaNase group showed beneficial effects of insulin compared with placebo; the effect was significant 
at 6 months (p<0.01), and persisted at 12 months (p=0.09; Fig. 2). 
 
 
 
 
Implication: These results suggest that the two delivery devices may be providing different doses of 
insulin to the CNS. The ViaNase device results are consistent with multiple previous studies. The 
POD had not been used previously in clinical trials with insulin, and thus was relatively untested in 
Table 1. Baseline Participant 
Characteristics 
N (F/M) 
289 (134 / 155) 
Age (years) 
70.95 ± 7.1 
Diagnosis (MCI/AD) 
   105 / 184 
MMSE 
  24.8 ± 2.7 
Logical Memory 
    2.1 ± 2.7 
APOE (ε4+/ε4-) 
    193 / 96 
Fig. 1 
Fig. 2 

V2: 02-October-2025 
IND #: 119232 
Page 17 of 33 
terms of delivery efficacy, although modeling in organoid nasal cavities was conducted to verify that 
the target amount of insulin was dispersed to the target location in the nasal cavity. These divergent 
results raise the possibility that specific characteristics of the device can affect delivery. Any future 
studies of intranasal insulin will need to utilize devices that have been demonstrated to effectively 
deliver insulin to the CNS. The proposed study will seek to verify and compare delivery of two doses 
of insulin with 3 devices in order to provide supportive evidence for future trials.  
 
4.1 
Rationale for Dosage Selection 
The dosage selected (20 and 40 International Units INI) have been used in two prior studies with positive 
results. 
 
4.2 
Rationale for Primary and Secondary Outcome Measures  
Previous work demonstrates that following intranasal insulin administration, insulin levels are increased 
in the CSF, reflecting entry into the CNS, and with the greatest increases over a 30 minute period after 
administration (Born et al. Nature Neuroscience, 2002 Jun;5(6):514-6). Establishing which device and 
which dose provides the greatest increase in CSF insulin will provide important evidence to be used in 
the design of future trials.  
 
Regarding secondary measures, in previous studies intranasal insulin acutely improved memory 
performance and affected CSF levels of AD biomarkers (Reger et al. 2008; Craft et al. 2012). Thus 
examining effects on these measures will provide supportive information about access to and efficacy 
in the CNS. 
 
4.3 
Rationale for Design of Trial  
This study is designed as an acute administration, proof of concept study to determine whether 
administration of intranasal insulin results in increased delivery to the CNS as evidenced by increased 
CSF insulin levels relative to baseline. 
 
4.4 
Rationale for Biofluids 
The CSF biomarkers insulin, Aβ42, Aβ40 and total tau will be measured. Plasma levels of insulin will 
be also assessed. Plasma and CSF samples obtained in this study will be banked so that other putative 
biomarkers may be measured by qualified investigators in the future given adequate rationale and 
feasibility.  
 
5.0 
STUDY OVERVIEW 
The study will consist of a single site, randomized, double-blind trial comparing the acute effects of INI 
(20 or 40 International Units) compared with baseline levels delivered with the Aptar CPS, VP7 or UDS 
devices on CSF insulin levels, AD biomarkers and memory. At study entry, participants will be 
randomized to receive either a 20 or 40 IU dose of insulin first, and the other dose on a second visit. 
Participants who are cognitively normal or who have aMCI (n=30) will be enrolled. The primary outcome 
measure will consist of CSF insulin levels. Secondary measures will include a memory test and CSF 
biomarker levels.  
 
5.1 
Study Population 
A total of 30 adults who are cognitively normal or diagnosed with aMCI will be enrolled in this trial. We 
expect to enroll approximately 50% of participants from each group. To determine eligibility, all 
participants will undergo cognitive assessment, physical and neurological examination, ECG, 
clinical/safety laboratory assessment, and interviews of the participant and study partner conducted by 
the investigators and staff of the Clinical Core of the Wake Forest Alzheimer’s Disease Research Center 
(ADRC). 
 
5.2 
Diagnosis Criteria 
Diagnoses will be assigned by consensus of investigators from the Clinical Core of the Wake Forest 
ADRC using criteria specified by the NIA and Alzheimer’s Association MCI workgroup (Petersen, Doody 

V2: 02-October-2025 
IND #: 119232 
Page 18 of 33 
et al. 2001, Albert, Dekosky et al. 2011). 
 
Criteria for cognitively normal adults: 
a) No evidence of significant cognitive impairment on objective testing 
 
Diagnosis of aMCI requires:  
a) Evidence of a decline in episodic memory (memory scores below age and education-based 
norms)  
b) General preservation of independence in functional abilities 
c) Absence of dementia  
 
5.3  
Inclusion Criteria 
The following inclusion criteria will be used:  
1. 
Age 45 to 85 (inclusive)  
2. 
Fluent in English  
3. 
Cognitively normal or diagnosis of aMCI  
4. 
Stable medical condition for 3 months prior to screening visit 
5. 
Stable medications for 4 weeks prior to the screening and study visits (exceptions may be made 
on a case by case basis by study physician)  
6. 
Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be 
clinically insignificant by the study physician  
 
5.4 
Exclusion Criteria 
The following exclusion criteria will be used:  
1. A diagnosis of dementia 
 
2. History of a clinically significant stroke 
 
3. Current evidence or history in past two years of epilepsy, head injury with loss of 
consciousness, any major psychiatric disorder including psychosis, major depression, bipolar 
disorder 
 
4. Diabetes (type I or type II) insulin dependent and non-insulin dependent diabetes mellitus 
 
5. Current or past regular use of insulin or any other anti-diabetic medication within 2 months of 
screening visit 
 
6. History of seizure within past five years 
 
7. Pregnancy or possible pregnancy 
 
8. Use of anticoagulants warfarin (Coumadin) and dabigatran (Pradaxa) 
 
9. Residence in a skilled nursing facility at screening 
 
10. Use of an investigational agent within two months of screening visit 
 
11. Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or any other 
exclusionary medications (exceptions may be made on a case by case basis by study 
physician)  
 
 
5.5 
Recruitment and Retention Strategies 
Recruitment will occur primarily from the Clinical Core of the Wake Forest ADRC. Some participants 
may also be identified from community recruitment efforts or from recently completed studies.  

V2: 02-October-2025 
IND #: 119232 
Page 19 of 33 
 
6.0 
STUDY TIMELINE  
The approximate timeline for this nine-month study is projected as follows: 1) approximately one months 
for study startup activities; 2) study visits will occur over a six-month period; 3) CSF and blood analyses, 
data analyses and study dissemination will occur over the final 2 months.  
 
7.0 
DESCRIPTION OF STUDY VISITS 
The “Schedule of Study Procedures and Assessments” in Table 4 provides an overview of study visit 
activities.  The primary and secondary outcome measure will be measured at both study visits. 
Genotyping will occur at Screening for participants who have not previously received APOE genotypes 
through the ADRC.  
 
7.1 
Screening (Visit 1) 
The purpose of this visit is to determine study eligibility.  Potential participants must sign an informed 
consent form and HIPAA Authorization prior to administration of any study-related procedures. After 
consent is obtained, participants will be given the MMSE, the CDR and Story Recall to determine study 
eligibility. Screening may be waived for participants who have received evaluations from the ADRC 
within the past 12 months.  
 
In addition, information regarding demographics, concurrent medications, medical history and adverse 
events will be gathered from the participant. Vital signs, height and weight will be measured. A brief 
physical and neurological examination (which include a nasal examination) and a standard 12-lead 
resting ECG will be performed. The ECG report will be reviewed, signed, and dated by the investigator 
or a medically qualified staff member as delegated by the Principal Investigator. Those with clinically 
significant ECG findings will be referred for follow-up as deemed appropriate by the investigator. These 
procedures may be waived for participants who have received evaluations from the ADRC within the 
past 12-months. 
 
Blood will be drawn for routine clinical laboratory evaluations. If values are outside of the laboratory’s 
normal range and determined clinically significant by the medically qualified study investigators, lab 
tests may need to be repeated and may be considered exclusionary for participation in the study. Blood 
samples will also be collected for ApoE genotyping and optional DNA storage.  
 
7.2 
Baseline (Visit 2) 
Results from all screening procedures must be reviewed and all inclusion/exclusion criteria must be met 
prior to proceeding to baseline. For participants whose screening visit was waived because they had 
received ADRC evaluations within the past 12-months will sign an informed consent form and HIPAA 
Authorization prior to administration of any study-related procedures. 
 
According to the randomization schedule, the participant will receive a dose of 20 or 40 International 
Units insulin with one of the three Aptar devices. They will then begin preparations for the lumbar 
puncture. After preparation, the immediate recall section of the AVLT will be administered. 
 
Lumbar puncture will then be performed in the morning after a minimum 8-hour overnight fast. After 
insertion of the spinal catheter, blood and CSF will be collected immediately. Insulin (20 or 40 IU) will 
then be administered, and additional CSF and blood will be collected following administration, and then 
the spinal catheter will be withdrawn.  Following the lumbar puncture, the delayed recall section of the 
AVLT will be administered. Participants will then receive a snack and instructions about post-lumbar 
puncture care. Site staff will call the participant within 24 hours from the lumbar puncture procedure to 
inquire about the participant’s well-being and possible adverse events. 
 
 
7.3 
Visit 3 
Visit 3 will be scheduled within 2 to 6 weeks following Visit 1. Vital signs and weight will be obtained, a 
nasal examination will be conducted, adverse events and concurrent medications will be recorded. 

V2: 02-October-2025 
IND #: 119232 
Page 20 of 33 
Procedures will follow the schedule outlined for Visit 1, except that the alternate dose of insulin will be 
administered.  
 
8.0 
STUDY-SPECIFIC PROCEDURES 
 
8.1 
Memory Evaluation Instruments Administered to the Participant 
Objective tests of cognitive function will include MMSE, Story Recall, and the Rey Auditory 
Verbal Learning Test.  
 
8.2 
Clinical and Functional Evaluations  
 
8.2.1 Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) 
The CDR (Hughes, Berg et al. 1982, Morris 1993) is a clinical scale that rates the severity of dementia 
as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). The 
score is based on interviews with the participant and study partner, using a structured interview that 
assesses six domains: memory, orientation, judgment and problem solving, community affairs, home 
and hobbies, and personal care.   
 
At Screening the CDR global score will be used for eligibility purposes. For all other administrations, 
the 6 domain scores will be summed to get the Sum of Boxes (SB) score. Training on the use of the 
CDR will be conducted to standardize its administration across sites. The CDR online training tool 
resides on the Washington University, St. Louis website, with oversight provided by Dr. John C. Morris 
(Morris, Ernesto et al. 1997).  
 
9.0 
STUDY METHODS 
 
9.1 
Safety Assessments 
At each study visit, all participants will undergo a nasal examination and any occurrence of adverse 
events will be reviewed and documented; concomitant medications will be recorded as well. In addition, 
24 hours after the Lumbar Puncture, each study participant, or a person designated to speak for them 
will be contacted by phone to confirm the participant’s well being and queried about any new adverse 
events. All adverse events will be reported to the study MD for review.  
 
9.2 
Physical and Neurological Examination 
A brief physical examination will be performed by a medically qualified professional at the screening 
visit. 
A 
review 
of 
the 
major 
body 
systems 
will 
be 
performed 
for 
example: 
skin, 
head/ears/eyes/nose/throat (HEENT), cardiovascular, pulmonary, abdomen, musculoskeletal, 
neurological, and gastrointestinal. Assessments of height (Screening visit only), weight, and vital signs 
(systolic and diastolic blood pressure, pulse, temperature, and respiration) are included. Neurological 
examination will include an assessment of cranial nerves, strength, coordination, reflexes, sensation, 
tremor and gait at every study visit. A nasal examination will also be performed. The examination will 
assess irritation or other abnormalities of the nares.  
 
9.3 
Electrocardiogram (ECG) 
A standard 12-lead resting ECG will be performed at Screening visit.  The ECG report will be reviewed, 
signed, and dated by the investigator.  Those with clinically significant ECG findings will be referred for 
follow-up as deemed appropriate by the investigator and may be excluded from the study. 
  
 
 
9.4 
Clinical Laboratory Evaluations 
All routine laboratory samples will be analyzed by a central laboratory, which will provide a procedures 
manual and supplies. Lab reports will be reviewed, signed and dated by the Study Physician.  If a value 
is outside of the laboratory’s normal range, the clinician will indicate if it is clinically significant or not. If 

V2: 02-October-2025 
IND #: 119232 
Page 21 of 33 
clinically significant, lab tests may need to be repeated and follow up with the participant’s PCP should 
occur.    
 
10.0 
BIOMARKER STUDIES 
 
10.1 
CSF 
All CSF samples will be collected in the morning before breakfast and after an overnight fast.  
Participants who are taking anticoagulants, warfarin (Coumadin) and dabigatran (Pradaxa) should not 
be screened for this trial, as these are prohibited medications. Based on clinician judgment and 
depending on the clinical indication, it may be suitable to discontinue participants from their anti-platelet 
agent (e.g., aspirin, Plavix, NSAIDs) for 5-7 days prior to lumbar puncture and until at least 24 hours 
after lumbar puncture.  It is not required that participants be discontinued from their anti-platelet agent 
in order to screen and enroll in the study.  
 
A minimal total volume of CSF (~25 ml) will be required for this study.  To clear any blood from minor 
trauma associated with needle insertion, the first 1-2 mL of CSF are discarded (or more if 
needed).  Collected CSF is aliquoted into sterile microtubes. Approximately 2ml of CSF or volume per 
local laboratory requirements will be sent at ambient temperature to the CRU laboratory for protein, 
glucose and cell count. CSF will be immediately frozen upright on dry ice for at least 20 minutes then 
stored at -70 until analysis.  
 
CSF samples will be used to measure levels of insulin, Aβ42, Aβ40, total tau, and phospho-tau181. 
Assays will be performed by the Wake Forest ADRC Biomarker Service. CSF samples will also be 
frozen and stored for future analysis of putative biomarkers. 
 
10.2 
Blood Collection at Lumbar Puncture Visits 
All samples will be collected in the morning before breakfast and after a minimum 8-hour overnight fast. 
Blood samples (10 ml) will be collected before and after insulin administration. Blood will be processed 
for fasting plasma insulin and glucose. Additional blood for plasma and serum will be processed and 
banked. 
 
10.3 
Genetic Samples, Storage and Future Use 
DNA will be extracted from participant blood samples and will be analyzed for ApoE genotyping. ApoE 
genotyping will be used as a weighting factor for the minimization strategy during randomization.  This 
will allow secondary analyses of data on the impact of the ApoE genotype on putative biomarkers of 
AD, clinical outcome measures, and adverse events. Participants will be asked to consent to optional 
DNA banking for future research studies. ApoE genotyping will be performed by Dr. Tim Howard under 
the auspices of the ADRC Biomarker service using established protocols.  
 
11.0 
STATISTICAL PLAN  
Statistical analyses will be conducted by the ADRC Biostatistics Core. To address the Primary Aim, 
CSF insulin values will be subjected to a repeated measures analysis of variance with dose and time 
as the repeated measures, device as the between subjects factor, with age and baseline MMSE as 
covariates. Secondary analyses will examine the effect of diagnostic status (cognitively normal vs. MCI) 
and APOE genotype. Secondary analyses will also examine treatment-related differences for other CSF 
and plasma biomarkers, and for memory scores.  
 
 
 
 
11.1 
Power Analyses 
As this study is designed as a proof of concept study power calculations have not been conducted.  
 
12.0 
POTENTIAL RISKS 

V2: 02-October-2025 
IND #: 119232 
Page 22 of 33 
 
12.1 
Safety of Intranasal Insulin 
Safety issues pertaining to INI administration for the treatment of diabetes have been extensively 
explored for over two decades (Pontiroli, Alberetto et al. 1982). For diabetes treatment, absorption 
enhancers must be used to increase the transport of insulin across the nasal membrane to the periphery 
due to the fact that peripheral bioavailablity of insulin without absorption enhancers is less than 1% 
(Illum 2002). A recent safety study of INI administration without absorption enhancers demonstrated no 
treatment induced changes in blood glucose levels, nasal airway patency, or transnasal pressure 
gradient (Kupila, Sipila et al. 2003). There are no known serious risks associated with INI without 
enhancers. A recent industry report raised the issue of rare but significant increases in lung cancer in 
smokers treated with inhaled insulin; six of 4740 patients taking inhaled insulin developed lung cancer 
compared with one of 4292 patients who received an active comparator (incidence per 100 patient 
years exposure, 0.13 vs 0.02). However, the inhaled insulin protocol used for diabetes treatment in this 
report included absorption enhancers to maximize delivery to lungs, whereas the nose-to-brain delivery 
device to be used in this study greatly minimizes lung delivery.  
 
Regarding the risk of hypoglycemia, at least five peer reviewed human studies (Kern, Born et al. 1999, 
Born, Lange et al. 2002, Kupila, Sipila et al. 2003, Benedict, Hallschmid et al. 2004, Stockhorst, de Fries 
et al. Submitted for publication)  and four preliminary studies (Reger, Watson et al. 2006, Reger, Watson 
et al. 2008, Reger, Watson et al. 2008) (Craft, Baker et al. 2012) revealed no change in blood glucose 
levels following intranasal insulin administration with doses that included 40 International Units 4 times 
daily for two months. There was one exception with the case of a single participant who experienced 
mild hypoglycemia (52 mg/dl) after skipping a meal and engaging in sustained vigorous exercise. In 
addition, a recent safety study (Kupila, Sipila et al. 2003) examined intranasal insulin administration of 
60 International Units once a day for three weeks in 21 healthy adults. This randomized, double-blind, 
placebo-controlled crossover trial measured blood glucose levels six times a day during the first two 
and the last two days of treatment. Pre- and post-treatment blood laboratory tests and nasal 
examinations were performed. The nasal studies included rhinoscopy to detect local irritation, a 
saccharin particle test to analyze mucocilary clearance, and rhinomanometry to evaluate nasal airway 
patency and transnasal pressure gradient. Results indicated no change in blood glucose values with 
insulin, and no change in the frequency of glucose values above 3.0 mmol/L.  
 
The only symptomatic hypoglycemic value occurred during placebo treatment. Insulin treatment had no 
effect on other laboratory values (C-peptide, total cholesterol, HDL, LDL, triglycerides, creatinine, 
glutamyl transferase), blood pressure, or body weight. In addition, nasal examinations revealed no 
adverse effects or functional disturbances following intranasal insulin administration. No serious 
adverse effects of treatment were observed in the preliminary studies (Reger, Watson et al. 2006, 
Reger, Watson et al. 2008, Reger, Watson et al. 2008, Craft, Baker et al. 2012). 
 
12.2 
Risks associated with use of the Aptar devices  
The Aptar devices have been extensively characterized and found to be safe for use. Further, because 
the use of the devices will be supervised directly by the study nurse the risks of adverse events is 
extremely low. Participants could experience some discomfort to their eyes or face if they do not hold 
the device to their nose as directed; however, again, the study nurse will carefully instruct and oversee 
device use so that any errors can be immediately corrected.  
 
 
 
 
 
12.3 
Lumbar Puncture 
Lumbar puncture may be associated with pain during the performance of the procedure. This is usually 
temporary and confined to the lower back. Headache may occur in about 5% of elderly people who 
undergo lumbar puncture. Less commonly, in about 1-4% of participants, a persistent low-pressure 

V2: 02-October-2025 
IND #: 119232 
Page 23 of 33 
headache may develop, probably due to leakage of CSF. Lower rates of post-LP headache have been 
noted in elderly patients, and when atraumatic (Sprotte) needles are used. If a post-LP headache 
persists it may need additional treatment, e.g. with fluids and analgesics. Uncommonly a blood patch 
(injection of some of the participant’s blood to patch the CSF leak) may be needed. Potential but rare 
risks of lumbar puncture include infection, damage to nerves in the back, and bleeding into the CSF 
space. The risk of these is much less than 1%.   
 
12.4 
Blood Draw 
The risks of blood draw include pain from the needle, bruising or infection at the site of venipuncture, 
or fainting as a response to blood draw.  Approximately 50mls of blood will be drawn for routine and 
biomarker laboratory assessments over the course of this study.   
 
13.0 
PERSONNEL REQUIREMENTS 
The following staff-member roles will be required to conduct the protocol.   
 
 
Principal Investigator: The Principal Investigator (PI; Suzanne Craft, PhD) is responsible for the 
overall conduct of the study. The PI will perform or supervise clinical evaluation of all participants 
and ensure protocol adherence. The PI will supervise project personnel and ensure that clinical 
raters maintain a high level of skill and accuracy in conducting assessments.  
 
Study Physician: Benjamin Williams, MD, PhD will serve as Study Physician for the trial. He will 
be responsible for conducting and supervising the medical evaluation (nasal examination, physical 
and neurological examinations), reviewing adverse events, interpreting laboratory results, and 
supervising clinical care provided to the participant during the study. He will also supervise, and on 
some occasions may perform the lumbar punctures. 
 
Study Clinician: Samantha Rogers, PA-C, MMS, will conduct the majority of the lumbar punctures. 
She has conducted more than 300 lumbar punctures for the ADRC and affiliated studies over the 
past 5 years. 
 
Study Nurse/Coordinator: Deborah Dahl, RN will serve as Study Nurse/Coordinator for the trial. 
She will be responsible for managing the day-to-day conduct of the trial.  Duties may include tracking 
recruitment, ensuring accurate administration of all instruments at the site, maintaining case report 
forms, processing of laboratory samples, and coordinating clinic visits. She will also oversee the use 
and maintenance of the devices, and coordinate with the Pharmacy regarding ordering and storage 
of saline and insulin.  
 
Interviewer/Psychometrician:  This person will be responsible for administering the memory 
assessments.   
 
CDR Rater: This person will render the CDR-SB rating based on clinical assessment of participant 
and study participant.  
 
Regulatory Affairs: Leslie Gordineer will be responsible for managing all regulatory related 
documents for the duration of the trial. 
 
14.0 
STUDY DRUG 
All participants will take receive two doses of INI (20 or 40 International Units).  
 
 
 
 
 
14.1 
Humulin® R U-100 Insulin 
Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) is a polypeptide hormone structurally 
identical to human insulin synthesized through rDNA technology in a special non-disease-producing 
laboratory strain of Escherichia coli bacteria. Humulin R U-100 has the empirical formula 

V2: 02-October-2025 
IND #: 119232 
Page 24 of 33 
C257H383N65O77S6 and a molecular weight of 5808 Da. Humulin R U-100 is a sterile, clear, aqueous, and 
colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and 
metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. 
The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to 
adjust the pH. 
 
More information about the Humulin® R U-100 insulin, including risks, contraindication and adverse 
reactions can be found in the the US package insert (USPI).  
 
14.2 
Randomization 
Eligible participants will be randomized to one of 3 devices. They will then be randomized on a 1:1 
schedule to receive either 20 or 40 IU of insulin.  
 
14.3 
Blinding 
Neither participants or site personnel will know which dose of insulin is being administered. Exceptions 
will be the study nurse who is directly involved in preparing the insulin. 
 
 
14.4 
Study Drug Dispensing 
Study drug will be inserted into the chamber of the device by the study nurse. 
 
14.5 
Intranasal Administration 
Insulin will be administered with one of three Aptar delivery devices (CPS, VP7 or UDS). These devices 
release a metered insulin dose into the participant’s nose, allowing the administration of smaller particle 
sizes to increase deposition in the upper nasal cavity while minimizing transport to the lungs. A volume 
of about 0.7 mL of insulin will be administered each time.  
 
14.6 
Storage   
Insulin will be maintained at a controlled temperature. 
 
14.7 
Drug Accountability   
The study nurse coordinator will maintain a log of study drug usage.  
 
15.0 
ADVERSE EVENTS 
 
15.1 
Definition 
An adverse event (AE) is defined as per the Code of Federal Regulation Title 21 Part 312. 
 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32 
 
Adverse events which occur after informed consent is signed include but are not limited to: (1) 
worsening or change in nature, severity, or frequency of conditions or symptoms present at the start of 
the study; (2) participant deterioration due to primary illness; (3) intercurrent illness; and (4) drug 
interaction. An abnormal laboratory value will only be reported as an AE if the investigator considers it 
to be an AE, or if it leads to the participant being withdrawn from the study. 
 
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and 
or other clinical information. In such cases, the diagnosis should be documented as the AE and not the 
individual signs or symptoms.  Symptoms and conditions present at the beginning of the study will be 
characterized, so that AEs can be defined as any new symptom, or any increase in frequency or severity 
of an existing symptom. 
Following questioning and evaluation, all AEs, whether determined to be related or unrelated to the 
study drug by a medically qualified site PI or clinician (MD, DO, NP or PA), must be documented in the 
participant’s medical records, in accordance with the investigator’s normal clinical practice, and on the 

V2: 02-October-2025 
IND #: 119232 
Page 25 of 33 
AE e-CRF. Each AE is evaluated for duration, severity, seriousness, and causal relationship to the study 
drug. 
 
15.2 
Following Up on AEs 
The investigator is obliged to follow participants with AEs until the events have subsided, the conditions 
are considered medically stable, or the participants are no longer available for follow up. Participants 
who discontinue due to adverse experiences will be treated and followed according to established 
medical practice. Adverse events will be rated as mild, moderate or severe.  This will also pertain to 
abnormal laboratory values deemed clinically significant by the site clinician.  
 
16.0 
SERIOUS ADVERSE EVENTS (SAE) 
 
16.1 
Definition  
A serious adverse event is defined as per the Code of Federal Regulation Title 21 Part 312  
 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32 
 
16.2 
Reporting SAEs 
Any serious and adverse event due to any cause, which occurs during the course of the investigation 
(i.e. anytime after informed consent, regardless of study drug exposure), will be reported to the PI and 
study physician within 24 hours of learning of the event. All serious adverse events will be reported to 
the Wake Forest IRB within 7 days of study personnel learning of the event. 
 
17.0 
ETHICS & REGULATORY CONSIDERATIONS 
 
17.1 
Ethical Standard 
Study investigators are charged with conducting this study in full conformity with: 
1. Good Clinical Practice (GCP) guidelines, as defined by the International Conference on 
Harmonisation (ICH) Guideline, Topic E6 
2. The United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) – Protection of 
Human Subjects 
3. 21CFR56 – Institutional Review Boards (IRBs) 
4. HIPAA 
5. State and Federal regulations and all other applicable local regulatory requirements and laws.    
 
Study personnel involved in conducting this study will be qualified by education, training and experience 
to perform their respective task(s) in accordance with GCP.   
 
17.2 
Institutional Review Board (IRB) 
This protocol and the associated informed consent documents and recruitment material will be 
approved by the Wake Forest IRB which is registered with the Office for Human Research Protections 
(OHRP). Any amendments to the protocol or consent materials must also be approved before they are 
placed into use. The investigator shall notify the IRB of deviations from the protocol or serious adverse 
events occurring at the site, in accordance with local procedures.  
 
 
 
 
 
 
17.3 
Informed Consent & HIPAA Authorization 
In obtaining and documenting informed consent, the investigator should comply with the applicable 
regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin 

V2: 02-October-2025 
IND #: 119232 
Page 26 of 33 
in the Declaration of Helsinki.  Prior to the beginning of the trial, the investigator should have the IRB’s 
written approval of the written informed consent form (ICF) and any other written information to be 
provided to participants.  Participants, their relatives, guardians, or authorized representatives and study 
partners will be given ample opportunity to inquire about the details of the study. Prior to a subject’s 
participation in the trial, the written informed consent form and HIPAA Authorization should be signed 
and personally dated by the subject and/or the subject’s legally authorized representative, the study 
partner and by the person who conducted the informed consent discussion.  Participants should be 
provided a copy of the signed ICF. 
 
The informed consent will not only cover consent for the trial itself, but for the genetic research, 
biomarker studies and biological sample storage. The consent for storage will include consent to access 
stored data and biological samples for secondary analyses. Consent forms will specify that DNA and 
biomarker samples are for research purposes only; the tests on the DNA and biomarker samples are 
not diagnostic in nature and participants will never receive results.  
 
17.4 
Participant Confidentiality | HIPAA 
Participant confidentiality is strictly held in trust by the participating investigators, research staff, and the 
sponsoring institution and their agents.  This confidentiality is extended to cover testing of biological 
samples and genetic tests in addition to the clinical information relating to participants. The study 
protocol, documentation, data and all other information generated will be held in strict confidence.  No 
information concerning the study or the data will be released to any unauthorized third party, without 
prior written approval. Any data, specimens, forms, reports, and other records that leave the site will be 
identified only by a subject identification number to maintain confidentiality.  All records will be kept in a 
locked file cabinet.  All computer entry and networking programs will be done using subject IDs only. 
Information will not be released without written permission of the subject, except as necessary for 
monitoring by the IRB, FDA, NIA, and the OHRP. 
 
Information about subjects will be kept confidential and managed according to the requirements of the 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed HIPAA Authorization informing the subject of the following:  
 
• What protected health information (PHI) will be collected from participants in this study 
• Who will have access to that information and why 
• Who will use or disclose that information 
• The rights of a research participant to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization. Each 
site PI, under the guidance of his/her IRB, is responsible for ensuring that all applicable HIPAA 
regulations and State laws are met. 
 
18.0 
GENETIC RESEARCH & STORAGE OF GENETIC MATERIAL  
The DNA is banked in locked freezers in the ADRC Biomarker Service.  Sample tubes are bar-coded 
and linked to participant ID number only and banked without personal identifiers.  
 
Only DNA from consenting participants will be banked and used to facilitate future research on aging 
and dementia, particularly in the discovery of genetic polymorphisms that may influence risk of 
developing AD.  Collection of DNA will permit investigators to probe candidate genetic polymorphisms 
as predictors of outcome in future studies.  The samples will be stored by the ADRC.  
  
 
 
18.1 
Storage of Biospecimen Samples  

V2: 02-October-2025 
IND #: 119232 
Page 27 of 33 
All biospecimens being banked for future AD biomarker research will be stored by the ADRC Biomarker 
Service.  
 
19.0 
RISKS AND BENEFITS ASSOCIATED WITH THIS STUDY 
 
19.1 
Potential Benefits of the Proposed Research to Human Subjects 
There is an urgent need to identify promising treatments for patients with AD and its prodrome aMCI. 
In a previous trial (Craft, Baker et al. 2012), intranasal insulin safely improved delayed memory and 
function in these patients. In a recent trial, these results were replicated with the subgroup of participants 
who used the ViaNase device, but not with the POD cohort. The proposed trial is designed to answer 
the important question of whether the ViaNase device is effective in delivering intranasal insulin into the 
CNS. This knowledge will enable the conduct of future Phase III trials of intranasal insulin.  
 
There are no significant potential clinical benefits for the participants in this study. Rather, there is a 
clear scientific benefit for the field as a whole. The relatively minor risks posed by the acute intranasal 
administration, cognitive testing, and LP are outweighed by the value of the scientific investigations 
outlined in this study. 
 
19.2 
Inclusion of Women and Minorities 
There are currently no studies that definitively support or negate the existence of significant differences 
in response to intranasal insulin in subgroups defined by gender or ethnic background. A specific goal 
percentage for women and minority enrollment is not set for this study. However, we will monitor minority 
enrollment throughout the study and make special effort to encourage minority enrollment. Minority 
enrollment will be facilitated through minority outreach effort coordinated by the Recruitment Core at 
the ADRC. No participant will be excluded due to his or her sex, race, or ethnic group.  
 
19.3 
Inclusion of Children as Participants in Research Involving Human Subjects 
Children will not be included. 
 
19.4 
Data and Safety Monitoring Plan  
The principal investigator and study clinician(s) will be responsible for the overall monitoring of the 
data and safety of study participants, with assistance by members of the study staff. Participants will 
be screened at the beginning of the study and will be monitored carefully at each study visit.  
Participants will be queried for serious adverse events (SAEs) and selected AEs (those temporally 
related to study procedures) at each study visit. All SAEs and selected AEs will be recorded on an AE 
case report form. Based on the nature of the AE, study clinicians will determine the severity of the 
event and association with the study.  All serious adverse events will be reported. Serious adverse 
events are defined as events that are (1) life-threatening or fatal, (2) result in severe or permanent 
disability, or (3) require hospitalization. SAEs will be reported to the IRB within 7 days of investigator 
knowledge of the event if they are related and unanticipated (i.e. if they qualify as an unanticipated 
problem). All serious adverse events will be followed until resolution, or 90 days after study 
participation has been terminated. 
 
"Severity" of events will be graded according to the following guidelines: 
 
1. 
Mild: The participant is aware of, but can easily tolerate, the event 
 
2. 
Moderate: The discomfort of the event is severe enough to interfere with some usual activities 
 
3. 
Severe: The participant is incapacitated, and unable to perform most or all usual activities 
 
 
 
The "study-relatedness" will be assigned according to the following guidelines: 

V2: 02-October-2025 
IND #: 119232 
Page 28 of 33 
 
1. Definitely Related: The reaction follows a reasonable temporal sequence and is known 
    to be an effect of participation or a procedure 
 
2. Possibly Related: The reaction follows a reasonable temporal sequence, and current  
medical knowledge does not preclude a relationship between participation or procedure  
and the event. 
 
3. Unlikely: Little evidence to suggest a causal relationship (e.g. the event did not occur within a 
reasonable time after administration of the trial medication) or another reasonable explanation for the 
event (e.g. another clinical condition or other concomitant treatment). 
 
4. Definitely Unrelated: Current medical knowledge precludes a causal relationship between 
participation or procedure and the event or the cause of the reaction is known to be other than 
participation or procedure. 
 
20.0 
PUBLICATION POLICY 
The results of this study may be published, depending on the results. 
 
21.0 
SHARING OF FINAL RESEARCH DATA 
Data from this research will be shared with other researchers pursuant to the 02/26/2003 “NIH Final 
Statement on Sharing Research Data”. NIH believes that data sharing is important for further translation 
of research results into knowledge, products, and procedures to improve human health.  The NIH 
endorses the sharing of final research data to serve these and other important scientific goals.  To 
protect subjects’ rights and confidentiality, identifiers will be removed from the data before they are 
shared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22.0 
TABLE 4: SCHEDULE OF PROCEDURES AND ASSESSMENTS 

V2: 02-October-2025 
IND #: 119232 
Page 29 of 33 
 
Visit # 
1 
2 
3 
Visit Name 
Screen 
Study 
1  
Study 
2 
 
 
 
 
Informed Consent 
X 
 
 
Demographics 
X 
 
 
Medical History 
X 
 
 
Concomitant Meds 
X 
X 
X 
Nasal Exam 
X 
X 
X 
Physical and Neurological Exam 
X 
 
 
Vital Signs 
X 
X 
X 
Height 
X 
 
 
Weight 
X 
 
 
ECG 
X 
 
 
Story Recall 
X 
 
 
MMSE 
X 
 
 
CDR 
X 
 
 
Adverse Events 
X 
X 
X 
Blood Draw 
X 
 
 
- Clinical Labs 
X 
 
 
- ApoE Genotyping | DNA Banking1 
X 
 
 
- Biomarkers | Plasma|Serum | Sample Banking 
 
X 
X 
LP 
 
X 
X 
- CSF Biomarkers | Banking2 
 
X 
X 
- post-procedure safety telephone check 
 
X 
X 
Auditory Verbal Learning Test 
 
X 
X 
1DNA banking is optional  
2CSF banking is optional 

V2: 02-October-2025 
IND #: 119232 
Page 30 of 33 
23.0 
LITERATURE CITED 
 
Albert, M. S., S. T. Dekosky, D. Dickson, B. Dubois, H. H. Feldman, N. C. Fox, A. Gamst, D. M. 
Holtzman, W. J. Jagust, R. C. Petersen, P. J. Snyder, M. C. Carrillo, B. Thies and C. H. Phelps (2011). 
"The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the 
National Institute on Aging and Alzheimer's Association workgroup." Alzheimers Dement. 
Baker, H. and R. F. Spencer (1986). "Transneuronal transport of peroxidase-conjugated wheat germ 
agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat." Exp Brain Res 
63(3): 461-473. 
Baker, L. D., D. J. Cross, S. Minoshima, D. Belongia, G. S. Watson and S. Craft (2011). "Insulin 
resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively 
normal adults with prediabetes or early type 2 diabetes." Arch Neurol 68(1): 51-57. 
Balin, B. J., R. D. Broadwell, M. Salcman and M. el-Kalliny (1986). "Avenues for entry of 
peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey." J 
Comp Neurol 251(2): 260-280. 
Benedict, C., M. Hallschmid, A. Hatke, B. Schultes, H. L. Fehm, J. Born and W. Kern (2004). 
"Intranasal insulin improves memory in humans." Psychoneuroendocrinology 29(10): 1326-1334. 
Benedict, C., W. Kern, B. Schultes, J. Born and M. Hallschmid (2008). "Differential sensitivity of men 
and women to anorexigenic and memory-improving effects of intranasal insulin." J Clin Endocrinol 
Metab 93(4): 1339-1344. 
Bodian, D. and H. A. Howe (1941). "Experimental studies on intraneuronal spread of poliomyelitis 
virus." Bull Johns Hopkins Hosp 68: 248-267. 
Born, J., T. Lange, W. Kern, G. P. McGregor, U. Bickel and H. L. Fehm (2002). "Sniffing 
neuropeptides: a transnasal approach to the human brain." Nat Neurosci 5(6): 514-516. 
Broadwell, R. D. and B. J. Balin (1985). "Endocytic and exocytic pathways of the neuronal secretory 
process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo." J Comp 
Neurol 242(4): 632-650. 
Cavanna, A. E. and M. R. Trimble (2006). "The precuneus: a review of its functional anatomy and 
behavioural correlates." Brain 129(Pt 3): 564-583. 
Chiu, S. L., C. M. Chen and H. T. Cline (2008). "Insulin receptor signaling regulates synapse number, 
dendritic plasticity, and circuit function in vivo." Neuron 58(5): 708-719. 
Craft, S., L. D. Baker, T. J. Montine, S. Minoshima, G. S. Watson, A. Claxton, M. Arbuckle, M. 
Callaghan, E. Tsai, S. R. Plymate, P. S. Green, J. Leverenz, D. Cross and B. Gerton (2012). "Intranasal 
insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial." 
Arch Neurol 69(1): 29-38. 
Craft, S., L. D. Baker, T. J. Montine, S. Minoshima, G. S. Watson, A. Claxton, M. Arbuckle, M. 
Callaghan, E. Tsai, S. R. Plymate, P. S. Green, J. Leverenz, D. J. Cross and B. Gerton (2012). 
"Intranasal Insulin Therapy for AD and MCI: A Pilot Clinical Trial." Arch Neurol 69: 29-38. 
Craft, S., E. Peskind, M. W. Schwartz, G. D. Schellenberg, M. Raskind and D. Porte, Jr. (1998). 
"Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of 
dementia and apolipoprotein E genotype." Neurology 50(1): 164-168. 
Craft, S. and G. S. Watson (2004). "Insulin and neurodegenerative disease: shared and specific 
mechanisms." Lancet Neurol 3(3): 169-178. 
De Felice, F. G., M. N. Vieira, T. R. Bomfim, H. Decker, P. T. Velasco, M. P. Lambert, K. L. Viola, 
W. Q. Zhao, S. T. Ferreira and W. L. Klein (2009). "Protection of synapses against Alzheimer's-linked 
toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers." Proc Natl Acad Sci U S 
A 106(6): 1971-1976. 

V2: 02-October-2025 
IND #: 119232 
Page 31 of 33 
Faber, H. K. (1938). "The early lesions of poliomyelitis after intranasal inoculation." J Pediat 13(1): 
10-37. 
Fairbrother, R. W. and E. W. Hurst (1930). "The pathogenesis of, and propagation of the virus in, 
experimental poliomyelitis." J Path Bact 33: 17-45. 
Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker 
LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. 
Arch Neurol. 2005 Oct;62(10):1539-44. "Hyperinsulinemia provokes synchronous increases in central 
inflammation and beta-amyloid in normal adults." 
Francis, G. J., J. A. Martinez, W. Q. Liu, K. Xu, A. Ayer, J. Fine, U. I. Tuor, G. Glazner, L. R. Hanson, 
W. H. Frey, 2nd and C. Toth (2008). "Intranasal insulin prevents cognitive decline, cerebral atrophy 
and white matter changes in murine type I diabetic encephalopathy." Brain 131(Pt 12): 3311-3334. 
Frey, W. H. (2002). "Intranasal delivery: Bypassing the blood-brain barrier to deliver therapeutic 
agents to the brain and spinal cord." Drug Delivery Technology 2(5): 46-49. 
Frolich, L., D. Blum-Degen, H. G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. Muschner, A. 
Thalheimer, A. Turk, S. Hoyer, R. Zochling, K. W. Boissl, K. Jellinger and P. Riederer (1998). "Brain 
insulin and insulin receptors in aging and sporadic Alzheimer's disease." J Neural Transm 105(4-5): 
423-438. 
Galasko, D., D. Bennett, M. Sano, C. Ernesto, R. Thomas, M. Grundman and S. Ferris (1997). "An 
inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's 
Disease Cooperative Study." Alzheimer Dis Assoc Disord 11 Suppl 2: S33-39. 
Gasparini, L., G. K. Gouras, R. Wang, R. S. Gross, M. F. Beal, P. Greengard and H. Xu (2001). 
"Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-
amyloid and requires mitogen-activated protein kinase signaling." J Neurosci 21(8): 2561-2570. 
Gil-Bea, F. J., M. Solas, A. Solomon, C. Mugueta, B. Winblad, M. Kivipelto, M. J. Ramirez and A. 
Cedazo-Minguez (2010). "Insulin levels are decreased in the cerebrospinal fluid of women with 
prodomal Alzheimer's disease." J Alzheimers Dis 22(2): 405-413. 
Grillo, C. A., G. G. Piroli, R. M. Hendry and L. P. Reagan (2009). "Insulin-stimulated translocation of 
GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent." Brain Res 1296: 35-45. 
Hallschmid, M., C. Benedict, B. Schultes, J. Born and W. Kern (2008). "Obese men respond to 
cognitive but not to catabolic brain insulin signaling." Int J Obes (Lond) 32(2): 275-282. 
Hong, M. and V. M. Lee (1997). "Insulin and insulin-like growth factor-1 regulate tau phosphorylation 
in cultured human neurons." J Biol Chem 272(31): 19547-19553. 
Hughes, C. P., L. Berg, W. L. Danziger, L. A. Coben and R. L. Martin (1982). "A new clinical scale 
for the staging of dementia." Br J Psychiatry 140: 566-572. 
Illum, L. (2002). "Nasal drug delivery: new developments and strategies." Drug Discov Today 7(23): 
1184-1189. 
Kern, W., J. Born, H. Schreiber and H. L. Fehm (1999). "Central nervous system effects of intranasally 
administered insulin during euglycemia in men." Diabetes 48(3): 557-563. 
Kristensson, K. and Y. Olsson (1971). "Uptake of exogenous proteins in mouse olfactory cells." Acta 
Neuropathol 19(2): 145-154. 
Kupila, A., J. Sipila, P. Keskinen, T. Simell, M. Knip, K. Pulkki and O. Simell (2003). "Intranasally 
administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults." 
Diabetes Metab Res Rev 19(5): 415-420. 
Lee, C. C., Y. M. Kuo, C. C. Huang and K. S. Hsu (2009). "Insulin rescues amyloid beta-induced 
impairment of hippocampal long-term potentiation." Neurobiol Aging 30(3): 377-387. 
Minoshima, S., K. A. Frey, N. L. Foster and D. E. Kuhl (1995). "Preserved pontine glucose 
metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis." J 
Comput Assist Tomogr 19(4): 541-547. 

V2: 02-October-2025 
IND #: 119232 
Page 32 of 33 
Minoshima, S., R. A. Koeppe, K. A. Frey and D. E. Kuhl (1994). "Anatomic standardization: linear 
scaling and nonlinear warping of functional brain images." J Nucl Med 35(9): 1528-1537. 
Morris, J. C. (1993). "The Clinical Dementia Rating (CDR): current version and scoring rules." 
Neurology 43(11): 2412-2414. 
Morris, J. C., C. Ernesto, K. Schafer, M. Coats, S. Leon, M. Sano, L. J. Thal and P. Woodbury (1997). 
"Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease 
Cooperative Study experience." Neurology 48(6): 1508-1510. 
Petersen, R. C., R. Doody, A. Kurz, R. C. Mohs, J. C. Morris, P. V. Rabins, K. Ritchie, M. Rossor, L. 
Thal and B. Winblad (2001). "Current concepts in mild cognitive impairment." Arch Neurol 58(12): 
1985-1992. 
Pontiroli, A. E., M. Alberetto, A. Secchi, G. Dossi, I. Bosi and G. Pozza (1982). "Insulin given 
intranasally induces hypoglycaemia in normal and diabetic subjects." Br Med J (Clin Res Ed) 
284(6312): 303-306. 
Reger, M. A., G. S. Watson, W. H. Frey, 2nd, L. D. Baker, B. Cholerton, M. L. Keeling, D. A. 
Belongia, M. A. Fishel, S. R. Plymate, G. D. Schellenberg, M. M. Cherrier and S. Craft (2006). 
"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE 
genotype." Neurobiol Aging 27(3): 451-458. 
Reger, M. A., G. S. Watson, P. S. Green, L. D. Baker, B. Cholerton, M. A. Fishel, S. R. Plymate, M. 
M. Cherrier, G. D. Schellenberg, W. H. Frey and S. Craft (2008). "Intranasal insulin administration 
dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older 
adults." Journal of Alzheimers Disease 13(3): 323-331. 
Reger, M. A., G. S. Watson, P. S. Green, C. W. Wilkinson, L. D. Baker, B. Cholerton, M. A. Fishel, S. 
R. Plymate, J. C. Breitner, W. DeGroodt, P. Mehta and S. Craft (2008). "Intranasal insulin improves 
cognition and modulates beta-amyloid in early AD." Neurology 70(6): 440-448. 
Rivera, E. J., A. Goldin, N. Fulmer, R. Tavares, J. R. Wands and S. M. de la Monte (2005). "Insulin 
and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's 
disease: link to brain reductions in acetylcholine." J Alzheimers Dis 8(3): 247-268. 
Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys. Hoboken, New Jersey, John 
Wiley & Sons, Inc. 
Sakane, T., M. Akizuki, Y. Taki, S. Yamashita, H. Sezaki and T. Nadai (1995). "Direct drug transport 
from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs." J 
Pharm Pharmacol 47(5): 379-381. 
Sano, M., R. Raman, J. Emond, R. G. Thomas, R. Petersen, L. S. Schneider and P. S. Aisen (2011). 
"Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild 
Cognitive Impairment But Not Alzheimer Disease." Alzheimer Dis Assoc Disord 25(2): 122-127. 
Selkoe, D. J. (2008). "Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and 
behavior." Behav Brain Res 192(1): 106-113. 
Shipley, M. T. (1985). "Transport of molecules from nose to brain: transneuronal anterograde and 
retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase 
applied to the nasal epithelium." Brain Res Bull 15(2): 129-142. 
Stockhorst, U., D. de Fries, Y. Schottenfeld-Naor, A. Huebinger, H. J. Steingrueber and W. A. 
Scherbaum (Submitted for publication). "Intranasally administered insulin and its CNS effects in 
healthy humans: unconditioned and conditioned responses." 
Stockhorst, U., D. de Fries, H. J. Steingrueber and W. A. Scherbaum (2004). "Insulin and the CNS: 
effects on food intake, memory, and endocrine parameters and the role of intranasal insulin 
administration in humans." Physiol Behav 83(1): 47-54. 

V2: 02-October-2025 
IND #: 119232 
Page 33 of 33 
Talairach, J. and P. Tournoux (1988). Co-planar stereotaxic atlas of the human brain: 3-dimensional 
proportional system: an aproach to cerebral imaging. New York, New York, Thieme Medical 
Publishers. 
Thorne, R. G., C. R. Emory, T. A. Ala and W. H. Frey, 2nd (1995). "Quantitative analysis of the 
olfactory pathway for drug delivery to the brain." Brain Res 692(1-2): 278-282. 
Thorne, R. G., G. J. Pronk, V. Padmanabhan and W. H. Frey, 2nd (2004). "Delivery of insulin-like 
growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following 
intranasal administration." Neuroscience 127(2): 481-496. 
Townsend, M., T. Mehta and D. J. Selkoe (2007). "Soluble Abeta inhibits specific signal transduction 
cascades common to the insulin receptor pathway." J Biol Chem 282(46): 33305-33312. 
Weiss, P. and Y. Holland (1967). "Neuronal dynamics and axonal flow, ii. The olfactory nerve as 
model test object." Proc Natl Acad Sci U S A 57(2): 258-264. 
Worsley, K. J., A. C. Evans, S. Marrett and P. Neelin (1992). "A three-dimensional statistical analysis 
for CBF activation studies in human brain." J Cereb Blood Flow Metab 12(6): 900-918. 
Zhao, L., B. Teter, T. Morihara, G. P. Lim, S. S. Ambegaokar, O. J. Ubeda, S. A. Frautschy and G. M. 
Cole (2004). "Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: 
implications for Alzheimer's disease intervention." J Neurosci 24(49): 11120-11126. 
Zhao, W. Q. and M. Townsend (2009). "Insulin resistance and amyloidogenesis as common molecular 
foundation for type 2 diabetes and Alzheimer's disease." Biochim Biophys Acta 1792(5): 482-496.